July 2018
Antimicrobial Stewardship Targets in Community-Acquired Pneumonia
July 18, 2018
Article
Infectious Diseases Focus
Antimicrobial stewardship programs (ASPs) are often tasked with addressing a wide scope of antimicrobial misuse with limited resources.
Acute Pain Management in the General Population
July 17, 2018
Article
Chronic Care Focus
Acute pain is one of the most common complaints that lead Americans to access the health care system, resulting in more than 115 million emergency department visits each year.
USP Chapter : Nonsterile Compounding Pharmacy Air Flow Considerations
July 16, 2018
Article
Safe Handling
USP Chapter 800 presents many challenges for pharmacies and other health care settings, especially compounding pharmacies.
340B Compliance: The Medicaid Exclusion File and Prevention of Duplicate Discounts
July 15, 2018
Article
Viewpoints
Health care providers participating in the 340B program are prohibited from contributing to duplicate discounts, or the scenario that exists when a manufacturer provides a discounted 340B price and a rebate to Medicaid for the same drug.
Overview of Heart Failure Pharmacotherapy
July 14, 2018
Article
Formulary Drug Review
Heart failure (HF) is estimated to cost Americans $30.7 billion each year, 68% of which is in direct costs and 32% in indirect ones, according to the American Heart Association (AHA).
Risks, Diagnosis, and Treatment of Non-Hodgkin Lymphoma
July 13, 2018
Article
Oncology Focus
Non-Hodgkin’s lymphoma (NHL) was the seventh most prevalent form of cancer in the United States in 2017, according to the National Cancer Institute.
Pharmacogenomics, Enzyme Competition, and the Evolution of Precision Prescribing
July 12, 2018
Article
Clinical Care Focus
It is understood that a person’s genetics determines traits such as eye, hair, and skin color and even the predisposition to contracting certain diseases.
Precision Pharmacotherapy: Ready for Prime Time?
July 11, 2018
Article
Editor’s Note
In general, there is a lack of adequate evidence from well-designed, controlled clinical trials demonstrating that the use of pharmacogenomic data to individualize drug therapy is directly related to improvements in clinical outcome in nononcology therapeutic areas.